CALM vs CTVA: Which Is the Better Buy in 2026?

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CALM and CTVA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CALM and CTVA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cal-Maine Foods is the largest producer of shell eggs in the United States by volume. The company sells approximately 1 billion dozen eggs annually, representing approximately 20% of US shell egg sales. Cal-Maine sells through grocery retailers, foodservice distributors, and other commercial customers, primarily across the southwestern and central US.

Full CALM guide

Corteva was formed in 2019 when DowDuPont spun off its agriculture business, and for most of its life it ran two segments: Seed (genetically improved corn, soybean, canola, and other crop seeds) and Crop Protection (herbicides, insecticides, fungicides, and biological products). That structure ended in October 2026, when Corteva completed the separation of its seed operations into a new independent company, Vylor Inc., which trades under the ticker VYLR. Corteva keeps the NYSE listing and the CTVA ticker as a crop protection and digital agriculture business, with a standalone revenue base reported at about $7.5 billion and projected 2025 EBITDA of about $1.4 billion. Headquartered in Indianapolis, Indiana. Chuck Magro has been CEO since 2021.

Full CTVA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CALM drivers: Avian influenza and supply disruption; Cage-free transition.
• CTVA drivers: A pure crop protection company after the Vylor spin-off; Biological products growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Avian influenza could eventually impact Cal-Maine facilities, creating direct production losses. For CTVA, commodity crop price cycles affect farmer purchasing power and Corteva revenue, and the company no longer has the seed business to cushion a weak chemistry year.

Pick CALM if you believe its drivers more; CTVA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CALM and CTVA guides.

CALM. Cal-Maine's valuation analysis is dominated by cyclical considerations. Trailing P/E is uninformative because earnings swing materially with egg prices. Normalized earnings analysis (looking at average earnings across a full price cycle) is more useful. The dividend is formula-based and tracks earnings.

CTVA. Post-spin Corteva is valued as a mid-cap crop chemicals company: about 11 times forward earnings and roughly $8.6 billion of market value, a long way from the premium the combined seed-and-chemistry company carried. Trailing figures on data sites (a P/E near 8, a dividend yield above 5%, TTM net income of ~$126 million) mix pre- and post-separation periods and per-share bases, so they are not a clean guide yet. UBS cut its price target to $15 from $90 with a Neutral rating; the cut tracks the smaller standalone company rather than a change in view, and the November 11, 2026 report will give the first clean standalone baseline.

Headline figures (approximate, early 2026): CALM shows revenue (ttm) ~$3 billion (varies materially with egg prices), operating margin Highly cyclical, 5-40% across cycles, net income (ttm) Highly cyclical, depends on price environment, eps (ttm) Cyclical; CTVA shows standalone revenue base (crop protection and digital) ~$7.5 billion, per post-spin reports, standalone ebitda (2025, projected) ~$1.4 billion, operating margin (ttm, yahoo basis) ~13%, market cap ~$8.6 billion at $12.94 (Oct 16, 2026).

CALM and CTVA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CALM and CTVA exposure against your real portfolio. It is not an investment adviser.